Evidence map›Paper›PMID 36084485›Full record

ArticleBiomaterials2022

Nanoradiosensitizer with good tissue penetration and enhances oral cancer radiotherapeutic effect.

Di Jing, Nian Jiang, Fengyi Wang, Chunping Mao, Shujun Han, Pui Yan Ho, Wenwu Xiao, Yuanpei Li, Jian Jian Li, Lu Zhang and 1 more

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Di JingDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA; Department of Oncology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Nian JiangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Fengyi WangDepartment of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Chunping MaoDepartment of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Shujun HanDepartment of Radiation Oncology, School of Medicine, University of California Davis, Sacramento, CA, USA.
Pui Yan HoDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Wenwu XiaoDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Yuanpei LiDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Jian Jian LiDepartment of Radiation Oncology, School of Medicine, University of California Davis, Sacramento, CA, USA.
Lu ZhangDepartment of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, China. Electronic address: zhanglu@sustech.edu.cn.
Kit S LamDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA; Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, CA, USA. Electronic address: kslam@ucdavis.edu.
Southern University of Science and Technology · CNUC Davis Comprehensive Cancer CenterCentral South University · CNUniversity of California, Davis · USUniversity of California Davis Medical Center · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
Therapeutic Targeting Agents for Ovarian CancerR01CA115483 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI LAM, KIT S · 2005 to 2019
$5.5M
HER2-targeting transformable nanotherapeutic platform against HER2+ cancersR01CA247685 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LAM, KIT S · 2020 to 2024
$3.1M
The rodent eye as a non-invasive window for understanding cancer nanotherapeuticsU01CA198880 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LAM, KIT S · 2015 to 2019
$2.9M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA115483NCI NIH HHS R01 CA247685NCI NIH HHS U01 CA198880
6 · The paper itself

Abstract

Low dose non-toxic disulfide cross-linked micelle (DCM) encapsulated paclitaxel (PTX) was found to be highly efficacious as a radiosensitizer against oral cancer preclinical model. Intensity-modulated radiation therapy was locally administered for three consecutive days 24 h after intravascular injection of DCM-[PTX] at 5 mg/kg PTX. DCM-[PTX] NPs combined with conventional radiotherapy (2 Gy) resulted in a 1.7-fold improvement in therapeutic efficacy compared to conventional PTX plus radiotherapy. Interestingly, we found that radiotherapy can decrease tight junctions and increase the accumulation of DCM-[PTX] in tumor sites. Stereotactic body radiotherapy (SBRT) given at 6 Gy was used to further investigate the synergistic anti-tumor effect. Tumor tissues were collected to analyze the relationship between the time interval after SBRT and the biodistribution of the nanomaterials. Compared to combination DCM-[PTX] with conventional radiation dose, combination DCM-PTX with SBRT was found to be more efficacious in inhibiting tumor growth.

Indexed as

MicellesMouth NeoplasmsCell Line, TumorDisulfidesHumansPaclitaxelTissue DistributionDisulfidesMicellesPaclitaxelNano-micelleOral cancerRadio-sensitizerRadiotherapy

Identifiers

PMID36084485
PMCPMC10021813
OpenAlexW4294091456

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read61
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.